Response to Fludarabine Regimens and Survival in Previously Untreated CLL by Pretreatment Characteristics
| Characteristics . | Value . | No. of Patients . | Median Survival (mo) . | P Value Log Rank . |
|---|---|---|---|---|
| Total | — | 174 | 67 | |
| Regimen | No Pred | 71 | 74 | NS |
| With Pred | 103 | 54 | ||
| Age (yr) | <60 | 84 | 75 | |
| 60-69 | 64 | 67 | <.001 | |
| ≥70 | 26 | 32 | ||
| Rai stage | I-II | 108 | 74 | .02 |
| III-IV | 66 | 51 | ||
| Binet stage | A | 53 | 74 | |
| B | 75 | 66 | NS | |
| C | 46 | 52 | ||
| Platelets (×103/μL) | <100,000 | 28 | 71 | NS |
| ≥100,000 | 146 | 63 | ||
| Hemoglobin (G%) | <11 | 54 | 47 | <.001 |
| ≥11 | 120 | 74 | ||
| White blood cell count (×103/μL) | <100,000 | 122 | 69 | .10 |
| ≥100,000 | 52 | 54 | ||
| Hepatomegaly | Yes | 24 | 47 | NS |
| No | 150 | 66 | ||
| Splenomegaly | Yes | 94 | 56 | NS |
| No | 80 | 67 | ||
| Node sites | 0 | 23 | 49 | |
| 1-2 | 69 | 67 | NS | |
| 3 | 81 | 58 | ||
| Blood urea nitrogen (mg%) | <23 | 145 | 71 | |
| ≥23 | 27 | 33 | <.001 | |
| LDH | Normal | 71 | 66 | |
| Elevated | 102 | 75 | NS | |
| β2M (mg%) | <3 | 36 | 75+ | |
| 3.0-3.9 | 21 | 55 | ||
| ≥4 | 26 | 56 | .05 | |
| IgG (mg%) | <650 | 41 | 67 | |
| ≥650 | 98 | 61 | NS | |
| IgA (mg%) | <75 | 65 | 56 | |
| ≥75 | 74 | 74 | NS | |
| IgM (mg%) | <30 | 28 | 54 | |
| ≥30 | 111 | 67 | NS | |
| Marrow cellularity (clot section) | <50 | 36 | 60 | |
| 50-84 | 68 | 67 | ||
| ≥85 | 57 | 49 | NS | |
| Marrow lymphocytes (%) | <70 | 43 | 55 | |
| 70-89 | 92 | 74 | ||
| ≥90 | 34 | 44 | .09 | |
| Cytogenetics* | Diploid | 100 | 83 | |
| Other | 34 | 53 | .02 | |
| Insufficient | 27 | 59 |
| Characteristics . | Value . | No. of Patients . | Median Survival (mo) . | P Value Log Rank . |
|---|---|---|---|---|
| Total | — | 174 | 67 | |
| Regimen | No Pred | 71 | 74 | NS |
| With Pred | 103 | 54 | ||
| Age (yr) | <60 | 84 | 75 | |
| 60-69 | 64 | 67 | <.001 | |
| ≥70 | 26 | 32 | ||
| Rai stage | I-II | 108 | 74 | .02 |
| III-IV | 66 | 51 | ||
| Binet stage | A | 53 | 74 | |
| B | 75 | 66 | NS | |
| C | 46 | 52 | ||
| Platelets (×103/μL) | <100,000 | 28 | 71 | NS |
| ≥100,000 | 146 | 63 | ||
| Hemoglobin (G%) | <11 | 54 | 47 | <.001 |
| ≥11 | 120 | 74 | ||
| White blood cell count (×103/μL) | <100,000 | 122 | 69 | .10 |
| ≥100,000 | 52 | 54 | ||
| Hepatomegaly | Yes | 24 | 47 | NS |
| No | 150 | 66 | ||
| Splenomegaly | Yes | 94 | 56 | NS |
| No | 80 | 67 | ||
| Node sites | 0 | 23 | 49 | |
| 1-2 | 69 | 67 | NS | |
| 3 | 81 | 58 | ||
| Blood urea nitrogen (mg%) | <23 | 145 | 71 | |
| ≥23 | 27 | 33 | <.001 | |
| LDH | Normal | 71 | 66 | |
| Elevated | 102 | 75 | NS | |
| β2M (mg%) | <3 | 36 | 75+ | |
| 3.0-3.9 | 21 | 55 | ||
| ≥4 | 26 | 56 | .05 | |
| IgG (mg%) | <650 | 41 | 67 | |
| ≥650 | 98 | 61 | NS | |
| IgA (mg%) | <75 | 65 | 56 | |
| ≥75 | 74 | 74 | NS | |
| IgM (mg%) | <30 | 28 | 54 | |
| ≥30 | 111 | 67 | NS | |
| Marrow cellularity (clot section) | <50 | 36 | 60 | |
| 50-84 | 68 | 67 | ||
| ≥85 | 57 | 49 | NS | |
| Marrow lymphocytes (%) | <70 | 43 | 55 | |
| 70-89 | 92 | 74 | ||
| ≥90 | 34 | 44 | .09 | |
| Cytogenetics* | Diploid | 100 | 83 | |
| Other | 34 | 53 | .02 | |
| Insufficient | 27 | 59 |
Abbreviation: NS, not significant.
Thirteen not performed.